Skip to contentP
Protagenic Therapeutics, Inc.\new
P
PTIXProtagenic Therapeutics, Inc.\new Q3 2020 · 10-Q
Revenue$0.00$0.00derivedno prior Q3 2019 on file Net Income-$1.05M-$1.05MN/M vs Q3 2019 EPS Diluted-$0.10-$0.10N/M vs Q3 2019 Operating Income-$1,092,016N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protagenic Therapeutics, Inc.\new · CIK 1022899 · Engraved from SEC EDGAR
Operating Cash Flowderived-$517,814N/M ended Sep 30, 2020 · filed Nov 16, 2020 · 47 d after period end